Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESILIENT trial of taldefgrobep alfa in spinal muscular atrophy
2024-511852-42-00Phase 3Authorised
- Sponsor
- Pfizer
- Start
- Jan 2023
- Modality
- Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial in spinal muscular atrophy (SMA) comparing Taldefgrobep alfa with Placebo (2 arms). Primary endpoint: Change from baseline in MFM-32 at Week 48. Planned start Jan 2023; status: authorised.
02
Drugs
taldefgrobep alfa
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on 2024-511852-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511852-42-00.